Reports Q3 revenue $14.5M, consensus $13.3M. “Our third-quarter results demonstrate clear progress in our strategy to Win-in-MRD,” said Chris Hall, Chief Executive Officer and President of Personalis (PSNL). “The 364% year-over-year growth in our clinical test volume is a powerful indicator of physician enthusiasm for NeXT Personal. We believe the compelling data from the AstraZeneca NeoADAURA and LAURA studies and the launch of our CATE trial with Yale are helping to build an unimpeachable evidence base for our technology. With our third indication submitted for Medicare coverage, we are well positioned for success in this large market.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- PSNL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Personalis Inc. Advances TNBC Treatment with Innovative ctDNA Study
- Personalis announces NeXT Personal data from AstraZeneca’s Phase 3 LAURA trial
- Personalis management to meet with Piper Sandler
- Personalis collaborates with Yale Cancer Center over CATE clinical trial